Navigation Links
Dendreon Reports Fourth Quarter and 2009 Year End Financial Results
Date:2/22/2010

"The positive results from our IMPACT study of PROVENGE made 2009 a momentous year for Dendreon and its stockholders as we initiated the transition to a commercial enterprise to serve patients with late-stage prostate cancer," said Mitchell H. Gold, M.D., president and chief executive officer.  "To continue this transformation in 2010, we are investing in our commercial and manufacturing infrastructure to support the launch of PROVENGE pending FDA approval."

Conference Call Information

Dendreon will host a conference call today at 1:30 p.m. PT, 4:30 p.m. ET. To access the live call, dial 1-800-260-8140 (domestic) or +1-617-614-3672 (international); the conference ID number is 15732512. The call will also be audio webcast and will be available from the Company's website at www.dendreon.com under the "Investor/Webcasts and Presentations" section. A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-888-286-8010 or +1-617-801-6888 for international callers; the conference ID number is 13123096. The replay will be available from 7:30 pm ET'/>"/>

SOURCE Dendreon Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Dendreon Announces Election of Ian Clark and Pedro Granadillo to Board of Directors
2. Dendreon Reports PROVENGE Regulatory and Commercialization Progress and Future Pipeline Plans at Analyst Event
3. Dendreon Presents Preclinical Data Demonstrating Activity of TRPM8 Agonist, D-3263, in Benign Prostatic Hyperplasia
4. Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer
5. Dendreon to Hold a Conference Call Tomorrow at 9:00 AM ET to Discuss Final Results of Phase 3 PROVENGE IMPACT Trial
6. Dendreon Presents Integrated Analysis of Clinical Data from NEUVENGE Trials at Chemotherapy Foundation Symposium
7. Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial
8. Dendreon to Hold a Conference Call Today at 9:00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial
9. Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October
10. Dendreon Initiates Phase 2 Trial of PROVENGE in Patients With Localized Prostate Cancer Prior to Surgery
11. Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Resources Group finds that the market for colorectal cancer (CRC) ... in the United States , ... Italy , Spain , the ... . The biosimilar erosion of Roche/Genentech/Chugai,s Avastin and Bristol-Myers Squibb/Eli ... of Eli Lilly,s Cyramza, Taiho Pharmaceutical,s Lonsurf, Alchemia,s HA-irinotecan and ...
(Date:8/28/2014)... , Aug. 28, 2014 Levi & ... commenced in the United States District Court for the ... of investors who purchased Galectin Therapeutics Inc. ("Galectin" or ... and July 28, 2014. For more information, ... alleges that during the Class Period the Company violated ...
(Date:8/28/2014)... -- Nonin Medical, Inc., the inventor of finger pulse ... announced that the Food and Drug Administration (FDA) has ... for use in the United States ... hub or kiosk through a USB connector and measures ... patients. The Model 3231 received EU certification last year. ...
Breaking Medicine Technology:The Colorectal Cancer Market Will Remain Steady at $7.7 Billion by 2023, With Biosimilar Erosion Of Key Agents Being Balanced Out By the Launch Of Premium-Priced Therapies 2SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Galectin Therapeutics Inc. and Its Board of Directors and a Lead Plaintiff Deadline of September 29, 2014 -- GALT 2Nonin Medical Announces FDA Clearance of Nonin Model 3231 USB Pulse Oximeter 2
... Also Receives Patent Covering ARIKACE for Once-Daily Treatment of ... June 25 Cystic Fibrosis Foundation Therapeutics Inc., the ... a $2.2 million award to Transave Inc., for the ... antibiotic that aims to treat Pseudomonas lung ...
... , Study shows 4% CHG antiseptic is effective against a ... Ga., June 24 Hand washing with a 4% chlorhexidine ... to stop the spread of the H1N1 Swine Flu Virus. ... Personnel Hand Antiseptic Towelettes have been tested and found to ...
Cached Medicine Technology:Transave Receives $2.2 Million Cystic Fibrosis Foundation Award for Development of ARIKACE(TM) 2Transave Receives $2.2 Million Cystic Fibrosis Foundation Award for Development of ARIKACE(TM) 3Transave Receives $2.2 Million Cystic Fibrosis Foundation Award for Development of ARIKACE(TM) 4Hand Washing with 4% CHG Antiseptic Kills Flu Viruses 2
(Date:8/29/2014)... 2014 Sansego is an ... interactive online community, and a range of personalized coaching ... the way to professional athletes. Crowie has brought together ... with him throughout the majority of his triathlon career. ... the triathlon public. , Sansego provides the following:, ...
(Date:8/29/2014)... RBS Reputation Management has brought a new ... service is to help those individuals and organizations that are ... Book. The service would push down the ranking of Scam ... fully invisible on Google. , RBS Reputation Management provides ... asked how company can provide guarantee of results with the ...
(Date:8/29/2014)... "After reading a study that said mortality ... I decided that there needed to be a way to ... a concerned inventor from Sikestons, Mo. , The Stand provides ... builds endurance and keeps the user from sitting too much. ... and producible in design variations, it's ideal for anyone who ...
(Date:8/29/2014)... basic life support (BLS) videos available on YouTube ... guidelines, according to a new study published in ... the Australasian College for Emergency Medicine (ACEM). ... arrest are known to improve survival for,victims. , ... together the study, which reviewed educational videos from ...
(Date:8/29/2014)... The Fresh Diet, America’s premier gourmet ... Fresh Vegetarian meal plan. Originating from The Fresh Diet’s ... menu is designed to satisfy customers seeking a convenient, ... , Responding to the growing demand by customers for ... market (Forbes) with 14% of Americans identifying vegetarian meals ...
Breaking Medicine News(10 mins):Health News:5 x World Champion Triathlete, Craig “Crowie” Alexander, Launches Online Triathlon Coaching Company – Sansego 2Health News:5 x World Champion Triathlete, Craig “Crowie” Alexander, Launches Online Triathlon Coaching Company – Sansego 3Health News:RBS Reputation Management Announces a New Online Reputation Management Service 2Health News:The Fresh Diet America's #1 At-Home Meal Delivery Company, Debuts Fresh Vegetarian Meal Plan Offering All-Natural Ingredients 2Health News:The Fresh Diet America's #1 At-Home Meal Delivery Company, Debuts Fresh Vegetarian Meal Plan Offering All-Natural Ingredients 3
... Watson Pharmaceuticals, Inc., a,leading specialty pharmaceutical company, ... Transdermal System patches sold in the United States ... recalled,patches are from Lot Number 92461850, have expiration ... Watson Laboratories, Inc. The affected lot of,Fentanyl Transdermal ...
... Aug. 8 The Health Resources,and Services Administration ... center grants to help people in need -- ... the comprehensive primary and preventive,health care services that ... care," said HRSA Administrator,Elizabeth Duke. "These awards will ...
... Aug. 8 MedQuist,Inc.,(Nasdaq: MEDQ ) the largest ... its results for the quarter ended June,30, 2008. Revenue ... compared,with $88.7 million in the second quarter of 2007. ... the prior year period was primarily due to,customer losses ...
... and drug addiction are polar opposite diseases, but both ... have enough of it; drug addicts get too much ... disorders has been well known, the way it works ... University,s Feinberg School of Medicine has revealed that dopamine ...
... cut behind uterus and into woman,s body cavity , , ... say may be the first operation of its kind ... University Medical Center removed a woman,s gallbladder without making ... part of an ongoing clinical research trial, involved insertion ...
... Receive $15 ... ... Mercy Health Plan, the,largest medical assistance care organization in Pennsylvania, ... that provides community-based, primary medical,dental and behavioral health care services, ...
Cached Medicine News:Health News:Watson Announces Limited Recall of Fentanyl Transdermal System 2Health News:Watson Announces Limited Recall of Fentanyl Transdermal System 3Health News:MedQuist Reports Second Quarter 2008 Results 2Health News:MedQuist Reports Second Quarter 2008 Results 3Health News:MedQuist Reports Second Quarter 2008 Results 4Health News:MedQuist Reports Second Quarter 2008 Results 5Health News:MedQuist Reports Second Quarter 2008 Results 6Health News:MedQuist Reports Second Quarter 2008 Results 7Health News:MedQuist Reports Second Quarter 2008 Results 8Health News:MedQuist Reports Second Quarter 2008 Results 9Health News:Why dopamine freezes parkinson patients and drives drug addicts 2Health News:Why dopamine freezes parkinson patients and drives drug addicts 3Health News:New Technique Removes Gallbladder Without External Incisions 2Health News:Keystone Mercy and DVCH to Offer Screenings for National Health Center Week 2
... 500 Power Supply is designed ... offers extensive programming capabilities, including ... methods for you to set ... simple, intuitive PowerEase® interface is ...
... The PowerEase® 500 Power ... mini-gel electrophoresis. It offers extensive ... and four custom methods for ... own preferences. The simple intuitive ...
... These modified battery chargers ... supplies for GENIE blotters. ... produce very specific voltages, ... than laboratory power supplies. ...
PS2A200 Power supply is a high current power supply ideal for all types of electrophoresis blotting and short electrophoresis runs....
Medicine Products: